Last reviewed · How we verify
Amodiaquine plus Artesunate co-administration — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Amodiaquine plus Artesunate co-administration (Amodiaquine plus Artesunate co-administration) — Kwame Nkrumah University of Science and Technology.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Amodiaquine plus Artesunate co-administration TARGET | Amodiaquine plus Artesunate co-administration | Kwame Nkrumah University of Science and Technology | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Amodiaquine plus Artesunate co-administration CI watch — RSS
- Amodiaquine plus Artesunate co-administration CI watch — Atom
- Amodiaquine plus Artesunate co-administration CI watch — JSON
- Amodiaquine plus Artesunate co-administration alone — RSS
Cite this brief
Drug Landscape (2026). Amodiaquine plus Artesunate co-administration — Competitive Intelligence Brief. https://druglandscape.com/ci/amodiaquine-plus-artesunate-co-administration. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab